Who Qualifies for Weight Loss Injections? (Complete Eligibility Guide)

By Emily

August 21, 2026 8 Min Read

The BMI thresholds, medical conditions, contraindications, and how the qualification process actually works

Weight loss injections are prescription medications — not supplements or over-the-counter products. This means there are specific medical criteria that determine who qualifies, who doesn’t, and under what circumstances a prescriber can and should prescribe them.

Understanding the qualification criteria before pursuing these medications saves time, sets realistic expectations, and helps people prepare for the evaluation process.

The Basic Qualification Criteria

The FDA approval criteria for weight loss injections — which form the basis for most prescribing decisions — are straightforward:

Criterion 1: BMI ≥ 30 (Obesity)

A Body Mass Index of 30 or above qualifies as obesity and meets the primary criterion for weight loss injection prescription — without requiring any additional health conditions.

BMI calculation: Weight (kg) ÷ Height (m)² — or use an online BMI calculator with your height and weight in imperial measurements.

BMI ≥ 30 examples:

5’4″ (163cm): 175 lbs or above
5’6″ (168cm): 186 lbs or above
5’8″ (173cm): 197 lbs or above
5’10” (178cm): 209 lbs or above
6’0″ (183cm): 221 lbs or above
6’2″ (188cm): 233 lbs or above

Criterion 2: BMI ≥ 27 (Overweight) + At Least One Weight-Related Condition

People with BMI between 27-29.9 (overweight but not obese) qualify if they have at least one weight-related health condition:

Qualifying conditions include:

Type 2 diabetes
Prediabetes
High blood pressure (hypertension)
High cholesterol (dyslipidemia)
Obstructive sleep apnea
Cardiovascular disease
Non-alcoholic fatty liver disease (NAFLD/NASH)
Osteoarthritis (weight-related joint disease)
Some prescribers include polycystic ovary syndrome (PCOS)

BMI 27-29.9 examples:

5’4″ (163cm): 157-174 lbs
5’6″ (168cm): 167-185 lbs
5’8″ (173cm): 177-196 lbs
5’10” (178cm): 188-208 lbs
6’0″ (183cm): 199-220 lbs

Contraindications — Who Should NOT Use Weight Loss Injections

Certain medical conditions disqualify people from using GLP-1 weight loss medications regardless of BMI or health conditions.

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC): GLP-1 receptor agonists caused thyroid C-cell tumors in rodent studies. While the human risk is uncertain, people with personal or family history of this specific thyroid cancer cannot use these medications.

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This genetic condition is associated with medullary thyroid carcinoma — the same contraindication applies.

Pregnancy: Weight loss injections are contraindicated during pregnancy. Animal studies show adverse fetal effects. Women who become pregnant while on these medications should stop immediately and inform their prescriber. Most guidelines recommend stopping medication at least 2 months before attempting conception.

Serious hypersensitivity to the medication: Prior severe allergic reaction to semaglutide, tirzepatide, or other components of the medication.

Relative Contraindications (Requires Careful Medical Assessment)

History of pancreatitis: GLP-1 medications carry a small increased risk of pancreatitis. People with a history of pancreatitis require careful risk-benefit assessment — many prescribers will not prescribe these medications to this population.

Severe gastrointestinal disease: Gastroparesis (delayed stomach emptying) — GLP-1 medications further slow gastric emptying, potentially worsening this condition significantly. Other severe GI conditions require assessment.

Severe kidney disease: While GLP-1 medications have shown kidney-protective benefits in mild-moderate kidney disease, severe kidney impairment (eGFR < 15) may require dose adjustment or avoidance.

Severe liver disease: Limited data in people with severe hepatic impairment.

Eating disorders: Active anorexia nervosa or bulimia nervosa — the appetite suppression of these medications could worsen restrictive eating patterns. Requires careful psychiatric evaluation.

Diabetic retinopathy: Rapid improvement in blood sugar control can temporarily worsen pre-existing diabetic eye disease. Ophthalmology evaluation may be appropriate before starting.

The Medical Evaluation Process

Understanding what happens during the qualification evaluation helps people prepare.

What Prescribers Assess

Medical history review:

Current and past medical conditions
Current medications (for interactions and contraindications)
Surgical history
Family medical history (particularly thyroid cancer, MEN 2)
Allergies

Physical measurements:

Current weight and height (for BMI calculation)
Blood pressure
Waist circumference (some providers)

Laboratory tests (often required):

Comprehensive metabolic panel (kidney and liver function)
HbA1c and fasting glucose (blood sugar status)
Thyroid function (TSH)
Lipid panel
Complete blood count
Some providers check thyroid antibodies

Psychiatric and behavioral assessment:

History of eating disorders
Mental health conditions that might affect treatment
Readiness and motivation for treatment

Telehealth Evaluation Process

Through telehealth providers — which is how most people now access these medications — the evaluation is conducted online:

Online intake form: Medical history, current medications, symptoms, health conditions
Prescription review: Prescriber reviews intake and any lab results
Virtual consultation: Video or asynchronous review with licensed prescriber
Prescription decision: Approved, approved with conditions, or declined with explanation
Lab requirements: Some telehealth providers require recent lab work; others can order labs through their platform

The entire process through telehealth typically takes 24-72 hours rather than the weeks of waiting associated with traditional in-person obesity medicine referrals.

Specific Populations and Qualification

Type 2 Diabetes

People with type 2 diabetes have the most straightforward qualification pathway — GLP-1 medications (Ozempic, Mounjaro, Victoza) are FDA-approved specifically for diabetes management, making insurance coverage more likely and the qualification process more standard.

For people with diabetes, the medication serves dual purposes: blood sugar management and weight loss. The prescribing physician managing their diabetes is often the most accessible prescriber.

Prediabetes

Prediabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%) qualifies as a weight-related condition for the BMI ≥ 27 criterion. Given that weight loss is the most effective intervention for preventing type 2 diabetes, weight loss injections are particularly well-justified in this population.

PCOS (Polycystic Ovary Syndrome)

PCOS is not always listed explicitly as a qualifying condition in FDA labeling — but many prescribers include it as a weight-related condition given the well-established relationship between obesity, insulin resistance, and PCOS severity.

As covered in our guide to weight loss injections for PCOS, GLP-1 medications have specific evidence for improving PCOS outcomes beyond weight loss alone — making a compelling clinical case for their use in this population.

Sleep Apnea

Obstructive sleep apnea is an explicit qualifying condition for the BMI ≥ 27 criterion. Notably, tirzepatide (Zepbound) has received FDA approval specifically for sleep apnea treatment alongside obesity — making qualification particularly well-supported for this indication.

Cardiovascular Disease

People with established cardiovascular disease and BMI ≥ 27 have the strongest clinical case for weight loss injections — the SELECT trial demonstrated 20% reduction in major cardiovascular events with semaglutide in this population. As covered in our guide to are weight loss injections safe long term, the cardiovascular benefit is one of the most compelling aspects of the long-term safety profile.

Older Adults (65+)

Age alone doesn’t disqualify anyone. Older adults with qualifying BMI and health conditions are appropriate candidates — though muscle preservation through adequate protein and resistance training is particularly important given age-related sarcopenia risk.

Younger Adults (18-25)

Weight loss injections are approved for adults aged 18 and above. Some prescribers may be more conservative with very young patients given limited data in this age group and the potential for decades of medication use.

Under 18: Wegovy is FDA-approved for adolescents aged 12 and above with obesity — a separate and more recently granted approval.

Men

Men qualify under the same criteria as women — BMI ≥ 30, or BMI ≥ 27 with a qualifying condition. Men tend to have higher rates of visceral fat and metabolic complications at lower BMI — making the qualifying conditions criterion particularly relevant.

As covered in our guide to weight loss injections for men, the clinical trial data shows comparable efficacy in men and women, though men may experience somewhat different side effect profiles.

When You Might Not Qualify Despite Meeting BMI Criteria

Meeting the BMI threshold doesn’t guarantee a prescription. Prescribers may decline to prescribe in situations including:

Insufficient medical evaluation: Some telehealth providers require recent lab work — if you don’t have recent results, they may require testing before prescribing.

Undisclosed contraindications: The evaluation reveals a contraindication that wasn’t initially apparent.

Medication interactions: Current medications that interact problematically with GLP-1 medications.

Active eating disorder: Current active anorexia or bulimia may lead prescribers to recommend eating disorder treatment before weight loss medication.

Pregnancy or breastfeeding: Immediate disqualification — medication is contraindicated.

Prescriber clinical judgment: Licensed prescribers can decline to prescribe based on clinical judgment even when basic criteria are met — this is appropriate medical practice.

The BMI Limitation — An Important Nuance

BMI is an imperfect measure — it doesn’t account for muscle mass, body composition, or fat distribution. Some specific situations:

High muscle mass: Athletes or muscular individuals may have BMI ≥ 27-30 without meaningful excess body fat. Most prescribers use clinical judgment alongside BMI — waist circumference and body composition context matters.

Normal BMI with metabolic disease: Some people have significant metabolic dysfunction (insulin resistance, fatty liver, visceral fat) at BMI below 27. While they technically don’t meet standard criteria, some physicians may prescribe off-label based on metabolic need.

Ethnic BMI adjustments: Some clinical guidelines recommend lower BMI thresholds for certain ethnic groups (particularly South Asian, East Asian populations) where metabolic complications occur at lower BMI — some prescribers apply these adjusted thresholds.

How to Prepare for Your Evaluation

Gather recent lab work: If you have recent blood tests (within the past 6-12 months) showing metabolic markers, have them available. This speeds the evaluation process.

Know your current medications: Have a complete list — including supplements — for drug interaction review.

Document weight-related conditions: If you have hypertension, diabetes, or other qualifying conditions, having documentation (diagnosis, current treatment) strengthens the case.

Know your family history: Specifically thyroid cancer and MEN 2 syndrome — these are direct contraindication questions.

Be honest about eating disorder history: This protects you — not disclosing relevant psychiatric history can lead to treatment that’s not appropriate for your situation.

How to Access Qualification Evaluation

Traditional pathway:

Referral from primary care physician to obesity medicine specialist
Often involves waiting lists
In-person visits required
Insurance prior authorization process

Telehealth pathway: Significantly more accessible — online evaluation, prescription if appropriate, medication shipped to home.

Gala offers licensed telehealth evaluation for weight loss injection qualification — reviewing your medical history, health conditions, and contraindications to determine whether GLP-1 compounded medication is appropriate for your situation.

[Check if you qualify at Gala →]

This is a paid partnership. Gala is a licensed telehealth provider. Medication is only prescribed following a medical consultation and is not guaranteed.

Quick Reference: Do You Qualify?

You likely qualify if:

✅ BMI ≥ 30 (no other conditions required)

✅ BMI 27-29.9 + type 2 diabetes

✅ BMI 27-29.9 + high blood pressure

✅ BMI 27-29.9 + high cholesterol

✅ BMI 27-29.9 + sleep apnea

✅ BMI 27-29.9 + cardiovascular disease

✅ BMI 27-29.9 + prediabetes

✅ BMI 27-29.9 + PCOS (many prescribers)

You likely don’t qualify if:

❌ BMI below 27 without qualifying conditions

❌ Personal or family history of medullary thyroid carcinoma

❌ MEN 2 syndrome

❌ Currently pregnant or breastfeeding

❌ Severe active pancreatitis

❌ Serious hypersensitivity to GLP-1 medications

Requires careful evaluation:

⚠️ History of pancreatitis

⚠️ Severe kidney or liver disease

⚠️ Active eating disorder

⚠️ Gastroparesis

⚠️ Pre-existing diabetic retinopathy

The Bottom Line

Qualification for weight loss injections is based on:

BMI ≥ 30 — qualifies without additional conditions
BMI 27-29.9 — qualifies with at least one weight-related health condition
No absolute contraindications — thyroid cancer history, MEN 2, pregnancy

The evaluation process through telehealth has made qualification assessment accessible within 24-72 hours rather than weeks of waiting for traditional in-person referrals.

If you meet the basic BMI criteria and don’t have obvious contraindications — the next step is a medical evaluation to confirm eligibility and establish the appropriate medication and starting dose.

For the complete picture on what these medications involve, see our guides to what are weight loss injections, how much they cost, and how fast they work.

Did you have questions about your eligibility that weren’t answered here? Leave them in the comments.